HER2 status in gastroesophageal cancer: a tissue microarray study of 1040 cases
- 1 May 2015
- journal article
- research article
- Published by Elsevier in Human Pathology
- Vol. 46 (5) , 665-672
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- HER2 status in gastric cancer: A comparison of two novel in situ hybridization methods (IQ FISH and dual color SISH) and two immunohistochemistry methods (A0485 and HercepTest™)Pathology - Research and Practice, 2013
- HER2 status in gastric cancers: a retrospective analysis from four Chinese representative clinical centers and assessment of its prognostic significanceAnnals of Oncology, 2013
- Early HER2 dysregulation in gastric and oesophageal carcinogenesisHistopathology, 2012
- HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the LiteratureJournal of Cancer, 2012
- Cost-effectiveness analysis of trastuzumab to treat HER2-positive advanced gastric cancer based on the randomised ToGA trialBritish Journal of Cancer, 2011
- Hybridization for human epidermal growth factor receptor 2 testing in gastric carcinoma: a comparison of fluorescence in-situ hybridization with a novel fully automated dual-colour silver in-situ hybridization methodHistopathology, 2011
- Genomic profiling of mitochondrion-rich breast carcinoma: chromosomal changes may be relevant for mitochondria accumulation and tumour biologyBreast Cancer Research and Treatment, 2011
- Advanced gastric cancer – Slow but steady progressCancer Treatment Reviews, 2010
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- Signal Transduction Proteins in Tumors From Puerto Rican and Caucasian Gastric Adenocarcinoma Patients: Expression Differences With Potential for Specific Targeted TherapiesDigestive Diseases and Sciences, 2008